Testing Whether Aspirin Prescriptions Are Feasible in Hidden Heart Artery Disease
Tests whether prescribing aspirin or not in people with early heart artery disease is feasible.
Plain-language title generated from the registry record
Registry title: Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial
Key facts
- Where
- Montreal, Québec, and Trois-Rivières, CanadaSee the 3 sites
- Phase
- Phase 3
Where in Canada
- Montreal Heart InstituteMontreal, CanadaTaking people
- Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)Québec, CanadaNot yet recruiting
- Centre hospitalier affilié universitaire régional (CHAUR)Trois-Rivières, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Montreal Heart Institute
- Trial code
- NCT07524335
- Record updated
- 9 November 2026
- Original description
In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.Read full original descriptionShow less
Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial
In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.
Inclusion: Documented coronary atherosclerosis, as defined by one of the following criteria:; Coronary artery calcium (CAC) score > 0; Cardiac CT angiography (CCTA) / CoroScan: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery; Coronary angiography: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease; Willing and able to provide informed consent and comply with study procedures.
Exclusion: Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication; History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure; History of significant bleeding within the past year; Any condition that, in the investigator's judgment, would make participation unsafe for the patient; Severe illness with limited life expectancy (i.e., <5 years); Clear contraindication to aspirin.